Verition Fund Management LLC Takes $82,000 Position in Metagenomi, Inc. (NASDAQ:MGX)

Verition Fund Management LLC acquired a new position in Metagenomi, Inc. (NASDAQ:MGX) during the third quarter, Holdings Channel.com reports. The firm acquired 37,675 shares of the company’s stock, valued at approximately $82,000.

Several other institutional investors have also recently made changes to their positions in the business. Rhumbline Advisers purchased a new stake in Metagenomi in the second quarter valued at $26,000. BNP Paribas Financial Markets lifted its holdings in shares of Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after buying an additional 7,256 shares during the period. XTX Topco Ltd purchased a new stake in shares of Metagenomi in the second quarter worth about $66,000. Resolute Advisors LLC grew its holdings in Metagenomi by 165.0% during the second quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock worth $108,000 after acquiring an additional 16,500 shares during the period. Finally, Green Alpha Advisors LLC purchased a new position in Metagenomi during the third quarter valued at approximately $69,000.

Metagenomi Price Performance

Shares of MGX opened at $3.39 on Wednesday. The stock’s 50 day moving average is $2.18 and its two-hundred day moving average is $3.21. Metagenomi, Inc. has a 12 month low of $1.61 and a 12 month high of $12.74.

Analyst Ratings Changes

Several research firms have commented on MGX. HC Wainwright upped their price objective on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and set a $15.00 price target on shares of Metagenomi in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.67.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.